In 2025, market figures stood at USD 6.73 billion in South Korea.
As per our research, the South Korea Infusion Services Market to reach USD 19.26 billion by 2033, with a forecasted CAGR of 14.0% across the projection period.
National Health Insurance coverage and advanced oncology infrastructure sustain high biologic infusion penetration, with university hospitals driving most administration volumes.
Korea Central Cancer Registry statistics confirm increasing treated cancer cases, supporting consistent infusion utilization across tertiary facilities.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]